Intellectual Property Law

New Matter SUMMER 2017 Volume 42, Number 2


3 Letter from the Chair
Elizabeth J. Rest

4 Letter from the Editor-in-Chief
Thomas A. Ward

5 Federal Government Expands Public
Disclosure Requirements For Clinical
Trials: Product Developers Must Publish
More Detailed Information, Study
Protocols, and the Results of Studies of
Unapproved/Unmarketed Products
Christina M. Markus
Beverly H. Lorell, M.D.
Elaine H. Tseng

10 Standing Still: Denial of Certiorari in
Belmora LLC v. Bayer Consumer Care AG
Leaves Question on Standing for Foreign
Plaintiff’s Unfair Competition Claims
Anna Raimer
Meredith Wilkes

Join CLA to access this page


Log in

Forgot Password

Enter the email associated with you account. You will then receive a link in your inbox to reset your password.

Personal Information

Select Section(s)

CLA Membership is $99 and includes one section. Additional sections are $99 each.